Non-small Cell Lung Cancer
Showing 1 - 25 of 1,515
Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma Trial in Irvine, Chicago, Boston
Not yet recruiting
- Advanced Solid Tumor
- +4 more
- FPI-2053
- +2 more
-
Irvine, California
- +2 more
Nov 27, 2023
Melanoma, NSCLC Trial (Evaluation of ctDNA using the F1T after 1 year of immunotherapy)
Not yet recruiting
- Melanoma
- Non-small Cell Lung Cancer
- Evaluation of ctDNA using the F1T after 1 year of immunotherapy
- (no location specified)
Nov 24, 2023
GSTP1 and Other Gene Polymorphisms With Platinum-induced
Not yet recruiting
- Non-small Cell Lung Cancer
- GSTP1 A313G (AA)
- (no location specified)
Nov 16, 2023
NSCLC Trial in Guangzhou (Hypofractionated radiotherapy, induction chemo-immunotherapy, concurrent chemo)
Recruiting
- Non-small Cell Lung Cancer
- Hypofractionated radiotherapy
- +4 more
-
Guangzhou, Guangdong, ChinaSun yat-sen university cancer center
Nov 14, 2023
Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)
Not yet recruiting
- Advanced Solid Tumor
- +8 more
- BGB-43395
- +2 more
- (no location specified)
Nov 13, 2023
NSCLC Trial in Shanghai (Toripalimab, Cryoablation)
Not yet recruiting
- Non-small Cell Lung Cancer
- Toripalimab
- Cryoablation
-
Shanghai, Shanghai, ChinaShanghai Chest Hospital
Nov 7, 2023
NSCLC Trial in Tianjing (Envalfolimab subcutaneously injected+Platinum-based doublet chemo intravenous injection,
Not yet recruiting
- Non-small Cell Lung Cancer
- Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection
- placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection
-
Tianjing, Tianjin, ChinaTianjin cancer hospital
Nov 3, 2023
NSCLC Trial in Guangzhou (BL-M07D1)
Not yet recruiting
- Non-small Cell Lung Cancer
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Nov 1, 2023
NSCLC Trial (HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin)
Not yet recruiting
- Non-Small Cell Lung Cancer
- HS-10241+ Almonertinib
- Pemetrexed + Cisplatin /Carboplatin
- (no location specified)
Oct 29, 2023
NSCLC, Oligoprogressive, Small-cell Lung Cancer Trial in Sacramento (Ablative local therapy)
Recruiting
- Non-small Cell Lung Cancer
- +2 more
- Ablative local therapy
-
Sacramento, CaliforniaUniversity of California, Davis
Oct 27, 2023
Huaier Granules in Postoperative Adjuvant Therapy for Non-small
Not yet recruiting
- Non-small Cell Lung Cancer
- Huaier granule
- Control
-
Shenyang, Liaoning, ChinaLiaoning Cancer Hospital & Institute
Oct 27, 2023
Pancreatic Ductal Adenocarcinoma, NSCLC, Colorectal Cancer Trial (AFNT-211)
Not yet recruiting
- Pancreatic Ductal Adenocarcinoma
- +4 more
- (no location specified)
Oct 23, 2023
NSCLC Trial (Tislelizumab IV, Tislelizumab SC, Histology-Based Chemotherapy Doublet)
Not yet recruiting
- Non-small Cell Lung Cancer
- Tislelizumab IV
- +2 more
- (no location specified)
Oct 25, 2023
NSCLC, Renal Cell Carcinoma, Melanoma Trial (Pembrolizumab co-formulated with hyaluronidase, Pembrolizumab)
Not yet recruiting
- Non-Small Cell Lung Cancer
- +2 more
- Pembrolizumab co-formulated with hyaluronidase
- Pembrolizumab
- (no location specified)
Oct 19, 2023
NSCLC Trial (Telisotuzumab Vedotin, Osimertinib, Cisplatin)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Telisotuzumab Vedotin
- +4 more
- (no location specified)
Oct 17, 2023
NSCLC Trial (Dupilumab, Cemiplimab)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Dupilumab
- Cemiplimab
- (no location specified)
Oct 12, 2023
NSCLC Trial in Iowa City ([18F]F-ARAG PET)
Not yet recruiting
- Non-small Cell Lung Cancer
- [18F]F-ARAG PET
-
Iowa City, IowaUniversity of Iowa Hospitals and Clinics
Oct 10, 2023
NSCLC Trial in Iowa City (Durvalumab, Pharmacological ascorbate, Surgery (SOC))
Not yet recruiting
- Non-small Cell Lung Cancer
- Durvalumab
- +2 more
-
Iowa City, IowaUniversity of Iowa
Oct 10, 2023
NSCLC Trial in Houston (Amivantamab, Tepotinib)
Not yet recruiting
- Non-small Cell Lung Cancer
-
Houston, TexasMD Anderson Cancer Center
Oct 9, 2023
NSCLC Trial in Shanghai (SH-1028 tablets, Placebo SH-1028 tablets)
Recruiting
- Non-small Cell Lung Cancer
- SH-1028 tablets
- Placebo SH-1028 tablets
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Oct 6, 2023
NSCLC Trial (V940, Pembrolizumab, Placebo)
Not yet recruiting
- Non-small Cell Lung Cancer
- V940
- +2 more
- (no location specified)
Oct 5, 2023
NSCLC Trial in Rockville (Crizotinib - Usual, Crizotinib - Study)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Crizotinib - Usual
- Crizotinib - Study
-
Rockville, MarylandMedicine Invention Design, Inc. - IORG0007849
Oct 5, 2023
NSCLC, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial (Nintedanib, gefitinib, erlotinib, afatinib)
Not yet recruiting
- Non-small Cell Lung Cancer
- +2 more
- Nintedanib, gefitinib, erlotinib, afatinib
- (no location specified)
Oct 2, 2023
OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain
Recruiting
- Non-small Cell Lung Cancer
-
Santiago de Compostela, Galicia, SpainLuis Ángel Leon Mateos
Oct 3, 2023
NSCLC, Neoadjuvant Therapy, Radiotherapy Trial in Yangzhou (drug, radiation, other)
Recruiting
- Non-small Cell Lung Cancer
- +3 more
- Toripalimab
- +2 more
-
Yangzhou, Jiangsu, ChinaPeople's hospital of northern jiangsu
Sep 26, 2023